Clinical Trial Update: Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tumor-infiltrating lymphocytes with low-dose interleukin-2 after cyclophosphamide and fludarabine in metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Tumor-infiltrating lymphocytes (TILs) therapy with low-dose interleukin-2

Snippet

Sponsor: University Health Network, Toronto | Conditions: Metastatic, Stage III or Stage IV, Melanoma | Phase 2 | Status: COMPLETED